Submit manuscript...
International Journal of
eISSN: 2470-9980

Vaccines & Vaccination

Letter to Editor Volume 2 Issue 2

Vaccine Allied Biologics

Ibrahim MSAW Shnawa

University of Qasim, Iraq

Correspondence: Ibrahim MSAW Shnawa, College of Biotechnology, University of Qasim, Qasim, Babylon, Iraq

Received: March 30, 2016 | Published: April 7, 2016

Citation: Shnawa IM (2016) Vaccine Allied Biologics. Int J Vaccines Vaccin 2(2): 00024. DOI: 10.15406/ijvv.2016.02.00024

Download PDF

Letter to Editor

One of the themes that are longly born in mind, those concerning “Vaccine versus Probiotics”. Then, if it is feasible to raise a question such as “Could we consider Probiotic as a vaccine, since they have an in-common indication, applications and/or attributes (Table 1). The common affairs are rather more than the different affairs. Thus, I think that they are forms of bio- therapeutics owning vaccine like potentials or one can say that they are vaccine-allied biologics.




Pathogens or their subunits

Certain commensal bacteria


Specific in most cases

Nonspecific in most cases


Stringent for human favor

Less stringent for human favor

Evaluation attitude

Needs special dispensing menu

Drug-like dispensing menu


Specific mostly

Nonspecific, mostly



Biotherapy of various immune defects in man and animals


Massive use rather than individual cases

On individual basis more than massive


Infectious, epidemic and pandemic threat or on travel to epidemic or endemic areas

Infectious and non-infectious

Disease nature

Based on affinity of B and T memory cells

Bacteriocin, immunomodulatory, anticancerous

Mode of action

Mild short duration like fever and ill

No appearent side effect

Side Effect

Due to vaccine or host born causes

Due to probiotic or host born causes


Table 1: Characteristics of vaccine versus probiotics.


  1. Banker DD (1980) Modren Practice In Immunization. Popular Prakshan, Bombay, India, pp. 384.
  2. Kaufmann SHE (2004) Novel Vaccination Strategies. Wiley-VCH, Germany, pp. 670.
  3. Kumar H, Salminen S, Vergagen H, Rowland I, Heimbach J, et al. (2015) Probiotics and prebiotics road to market. Curr Opin Biotech 32: 99-103.
  4. Quigley EMM (2016) Leaky gut-Concept or clinical entity. Curr Opin Gastroenterol 32(2): 74-79.
Creative Commons Attribution License

©2016 Shnawa. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and build upon your work non-commercially.